Besides hypersensitivity reactions to ziprasidone or any formulation excipients, there are several contraindications listed below.

- Patients with a known history of QT prolongation (including congenital long QT syndrome)

- Patients with uncompensated heart failure

- Patients with recent acute myocardial infarction

- Patients taking medicines that have demonstrated QT prolongation including Class Ia and III antiarrhythmics, dofetilide, sotalol, quinidine, thioridazine, mesoridazine, chlorpromazine,  pimozide, droperidol, sparfloxacin, moxifloxacin, gatifloxacin, halofantrine, pentamidine, mefloquine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, or tacrolimus.

**Warning/Precautions**

- Patients taking other drugs that act on the central nervous system (CNS) should also not be administered the drug due to additive adverse reaction potential.

- Many antihypertensive agents increase their effects when used with ziprasidone, leading to hypotension.

- ziprasidone dopamine D2 receptor antagonism may counter the therapeutic effect of levodopa and dopamine agonists.